Molecular imaging in oncology

Recent Results in Cancer Research

Volumn 187, Issue , 2013, Pages 371-400

  Lopci, Egesta ^a   Fanti, Stefano ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; ACETIC ACID C 11; ANGIOGENESIS INHIBITOR; CHOLINE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYLTYROSINE F 18; METHIONINE C 11; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ANTIANGIOGENIC THERAPY; ARTICLE; BLADDER CANCER; BONE METASTASIS; BRAIN CANCER; CANCER GRADING; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GLIOMA; HEAD AND NECK CANCER; HUMAN; HYPOXIA; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TUMOR RECURRENCE; TUMOR VASCULARIZATION; GENETICS; NEOPLASM; REVIEW;

HUMANS; MOLECULAR IMAGING; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 84871830741     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10853-2_13     Document Type: Article

References (265)

1. Ackerstaff E, Pflug BR, Nelson JB et al (2001) Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 61:3599-3603
2. Agid Y, Graybiel AM, Ruberg M, et al (1990) The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Adv Neurol 53:83-100
3. Ahlström H, Eriksson B, Bergstrom M et al (1995) Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195:333-337
4. 11CC-Acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 34:185-196
5. 11C-acetate: experimental and patient studies. Circulation 64(Suppl IV) IV 75
6. 11C-acetate. Circulation 62(Suppl III) III-74
7. 18FDOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37(1):46-48
8. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 35(8):1431-1438
9. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63:3791-3798
10. 18F]fluorothymidine into L178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32(3):257-263
11. 18F-FDOPA PET. J Nucl Med 45(7):1161-1167
12. 18F] FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31:1659-1672
13. 18F]galacto- RGD identifies the level of integrin avb3 expression in man. Clin Cancer Res 12:3942-3949
14. 99mTc-methylene diphosphonate. Semin Nucl Med 31:28-49
15. Blau M, Nagler W, Bender MA (1962) A new isotope for bone scanning. J Nucl Med 3:332-334
16. 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 15:85-94
17. Borelli MI, Villar MJ, Orezzoli A et al (1997) Presence of DOPA decarboxylase and its localisation in adult rat pancreatic islet cells. Diabetes Metab 23:161-163
18. Brandi G, Nannini M, Pantaleo MA et al (2008) Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. Chemotherapy 54(6):421-424
19. 11C methionine positron emission tomography (PET) data-results of a pilot study in 32 surgical cases. Acta Neurochir 144:777-782
20. 11C-Choline positron emission tomography. Int J Radiat Oncol Biol Phys 77:160-164
21. Briganti A, Chun FK-H, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49:1019-1027
22. Brown JM (1999) The hypoxic cell: A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 59:5863-5870
23. 18F]fluorothymidine. Clin Cancer Res 14:2970-2977
24. Buck AK, Hetzel M, Schirrmeister H et al (2005) Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 32:525-533
25. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 62:3331-3334
26. 18F]FLT for monitoring response to antiproliferative therapy in a mouse lymphoma xenotransplant model. J Nucl Med 45:434
27. Cai W, Chen K, Mohamedali KA et al (2006) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47:2048-2056
28. Cai W, Gambhir SS, Chen X (2008) Chapter 7. Molecular imaging of tumor vasculature. Methods Enzymol 445:141-176
29. Caldwell JH, Revenaugh JR, Martin GV et al (1995) Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 36:1633-1638
30. 11Ccholine PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 50:1394-1400
31. 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase\1.5 ng/ml? Eur J Nucl Med Mol Imaging 38:55-63
32. Cater DB, Silver IA (1960) Quantitative measurements of oxygen tension in normal tissues and in tumors of patients before and after radiotherapy. Acta Radiol 53:233-256
33. 11C-acetate applied in the liver with positron emission tomography. IEEE Trans Med Imaging 23:426-432
34. 18F-FDG. J Nucl Med 46(6):945-952
35. Chen X, Sievers E, Hou Y et al (2005b) Integrin avb3-targeted imaging of lung cancer. Neoplasia 7:271-279
36. 18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33:1387-1398
37. 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47:410-418
38. 11C-acetate and PET/ CT in prostate cancer. J Nucl Med (Suppl 2):46
39. 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:176-182
40. 18F-30- fluoro-30-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med 45:1677-1682
41. 18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med 30:1367-1372
42. 11C. Eur J Nucl Med 1:11-14
43. Cook GJ, Maisey MN, Fogelman I (1999) Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 26:1363-1378
44. Crabtree HG, Cramer W (1933). The action of radium on cancer cells I and II. Some factors determining the susceptibility of cancer cells to radium. Proc R Soc Ser B 113:238-250
45. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44:32-38
46. 11C-choline PET: first clinical experience. Eur J Nucl Med 29:1283-1288
47. 18F]fluoro-L-DOPA. Appl Radiat Isot 51:389-394
48. Dearling JL, Lewis JS, Mullen GE et al (2002) Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 7:249-259
49. Dearling JLD, Lewis JS, Mullen GE et al (1998a) Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 25:788-792
50. Dearling JLJ, Lewis JS, Welch MJ et al (1998b) Redox-active complexes for imaging hypoxic tissues: structure-activity relationships in copper(II)bis(thiosemicarbazone) complexes. Chem Commun 22:2531-2533
51. 18F labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61:110-117
52. Dehdashti F, Grigsby PW, Mintun MA et al (2003a) Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 55:1233-1238
53. Dehdashti F, Mintun MA, Lewis JS et al (2003b) In vivo assesment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30:844-850
54. 11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma. J Nucl Med 44:222-223
55. 11C]L-methionine uptake in gliomas. Neurosurgery 25:720-728
56. 18F-FDG and water using compartment and noncompartment analysis. J Nucl Med 42:248-256
57. 11C-acetate. J Nucl Med 44:556-558
58. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 30:1407-1412
59. Eidelberg D (1992) Positron emission tomography studies in parkinsonism. Neurol Clin 10:421-433
60. Eriksson B, Bergstrom M, Sundin A et al (2002) The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci 970:159-169
61. Eshuis SA, Jager PLÛ, Maguire RP et al (2009) Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging 36:454-462
62. Eshuis SA, Maguire RP, Leenders KL et al (2006) Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging 33:200-209
63. 18F-fluoride PET/CT. J Nucl Med 45:272-278
64. 18F-fluoride PET/CT. J Nucl Med 47:287-297
65. Fanti S, Nanni C, Ambrosini V et al (2007) PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging. 51:260-271
66. 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46:1642-1649
67. 18F-labeled tyrosine derivatives: synthesis and experimental studies on accumulation in tumors and abscesses. Bioorg Khim 35:334-343
68. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803
69. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611
70. Ferrara N (2005) The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 94:209-231
71. Fiebrich HB, Brouwers AH, Kerstens MN et al (2009) 6-[F-18]Fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 94:3922-3930
72. 18F]fluoro-L-dopa. J Nucl Med 25:1228-1233
73. 18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519-527
74. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286
75. 18F]fluoro-2- deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 30:988-994
76. Fujibayashi Y, Taniuchi H, Yonekura Y et al (1997) Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 38:1155-1160
77. 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 24:485-492
78. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305:137-138
79. Gazdar AF, Helman LJ, Israel MA et al (1988) Expression of neuroendocrine cell markers Ldopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res 48:4078-4082
80. 11C] choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35:1065-1073
81. Goldman S, Levivier M, Pirotte B et al (1997) Regionalmethionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38:1459-1462
82. Goodman MM, Keil R, Shoup TM et al (1997) Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med 38:119-126
83. 18F]-Fluorodopamine positron emission tomography J Clin Endocrinol Metab 88:637-641
84. 18F-fluoride: applying new technology to an old tracer. J Nucl Med 49:68-78
85. Gray LH, Conger AD, Ebert M et al (1953) Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648
86. 11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 63:64-74
87. 18F]FDG PET in clinical oncology. Lancet Oncol 8:822-830
88. 11C- Methionine positronemission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 68:19-23
89. Hara T, Yuasa M, Yoshida H (1997a) Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroethyl- dimethyl-2-oxyethylammonium. J Nucl Med 38:44
90. Hara T, Kosada N, Kondo T et al (1997b) Imaging of brain tumor, lung cancer, esophageal cancer, colon cancer, prostate cancer and bladder cancer with (C-11)choline. J Nucl Med 38:250
91. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39:990-995
92. 18F]- Fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43:187-199
93. 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 99:474-479
94. 18F-fluorodopa PET scan. J Pediatr 150:140-145
95. 18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab 92:4706-4711
96. Hatazawa J, Ishiwata K, Itoh M et al (1989) Quantitative evaluation of L-[methyl-C- 11]methionine uptake in tumor using positron emission tomography. J Nucl Med 30:1809-1813
97. 18F-fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 40:1367-1373
98. Heiss WD, Wienhard K, Wagner R et al (1996) F-Dopa as an amino acid tracer to detect brain tumours. J Nucl Med 37:1180-1182
99. 11C-methionine PET for differential diagnosis of lowgrade gliomas. Neurology 50:1316-1322
100. 11C-methionine PET for detection and localization of suspected parathyroid adenomas. Mol Imaging Biol 11:356-363
101. Hetzel M, Arslandemir C, Konig HH et al (2003) F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, costeff ectiveness, and impact on patient management. J Bone Miner Res 18:2206-2214
102. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027
103. Hicks RJ, Rischin D, Fisher R et al (2005) Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32:1384-1391
104. Ho CL, Chen S, Yeung DW et al (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48:902-909
105. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44:213-221
106. 18F-DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology 220:373-380
107. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71
108. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30:689-694
109. 18F DOPA whole body PET-initial results. Radiology 222:507-512
110. Hoffman RM (1984) Altered methionine metabolism, DNA methylation and oncogenic expression in carcinogenesis. Biochem Biophys Acta 738:49-87
111. Hood JD, Bednarski M, Frausto R, et al (2002) Tumor regression by targeted gene delivery to neovasculature. Science 296:2404-2407
112. Howard BV, Howard WJ (1975) Lipids in normal and tumor cells in culture. Prog Biochem Pharmacol 10:135-166
113. 11C-methionine- PET. J Clin Neurosci 12:775-780
114. 18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35:253-263
115. Hustinx R, Pourdehnad M, Kaschten B et al (2005) PET imaging for differentiating recurrent brain tumours from radiation necrosis. Radiol Clin North Am 43:35-47
116. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110:673-687
117. 18F]FDG PET/CT: a preliminary study. Appl Radiat Isot 67:1195-1198
118. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med 50:513-519
119. Ito Y, Fujita M, Shimada S et al (1999) Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse 31:178-185
120. 11C]methionine PET: case report.NeurolMed Chir (Tokyo) 41:415-418
121. Iwata Y, Shiomi S, Sasaki N et al (2000) Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 14:121-126
122. 18F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 30:1266-1269
123. Jeong JM, Hong MK, Chang YS et al (2008) Preparation of a promising angiogenesis PET imaging agent: 68 Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4, 7-triazacyclononane- 1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 49:830-836
124. 18F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging. 29:648-654
125. 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien) 104:8-12
126. Kang DE, White RL Jr, Zuger JH et al (2004) Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171:1806-1809
127. Kaschten B, Stevenaert A, Sadzot B et al (1998) Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 39:778-785
128. 11C- methionine uptake in low-grade gliomas and correlation with proliferative activity. Am J Neuroradiol 29:1867-1871
129. 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin Med 6:240-244
130. Kelloff GJ, Hoffman JM, Johnson B et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and drug development. Clin Cancer Res 11:2785-2808
131. 18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65:10104-10112
132. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. NatRev Cancer 2:727-739
133. 18F-FDG PET. Eur J Nucl Med Mol Imaging 32:52-59
134. Koh WJ, Bergman KS, Rasey JS et al (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33:391-398
135. Koh W-J, Rasey JS, Evans ML (1992) Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22:199-212
136. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 49:1944-1951
137. Kotzerke J, Prang J, Neumaier B et al (2000) Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 27:1415-1419
138. Kotzerke J, Volkmer BJ, Neumaier B et al (2002) Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med 29:1380-1384
139. 11C]- lmethionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 30:868-873
140. 11C choline PET/TC depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18-23
141. Krebs HA (1948) The tricarboxylic acid cycle. Harvey Lect Ser 44:165-99
142. Laforest R, Dehdashti F, Lewis J et al (2005) Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging. 32:764-770
143. 18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287-294
144. 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism. A pilot study. Nuklearmedizin. 45:193-196
145. 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36:73-92
146. Lapela M, Leskinen-Kallio S, Varpula M et al (1994) Imaging of uterine carcinoma by carbon- 11-methionine and PET. J Nucl Med 35:1618-1623
147. Lee CS, Samii A, Sossi V et al (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47:493-503
148. Leenders KL, Salmon EP, Tyrrell P et al (1990) The nigro-striatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47:1290-1298
149. 11C] methionine in assessment of response in non-Hodgkin lymphoma. Lancet 336:1188
150. Leskinen-Kallio S, Någren K, Lehikoinen P et al (1992) Carbon-11-methionine and PET is an effective method to image head and neck cancer. J Nucl Med 33:691-695
151. 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 64:1121-1124
152. Lewis JS, McCarthy DW, McCarthy TJ et al (1999) Evaluation of 64Cu-ATSM in vivo and in vitro in a hypoxic tumor model. J Nucl Med 40:177-183
153. Lewis JS, Welch MJ (2001) PET imaging of hypoxia. Q J Nucl Med 45:183-188
154. Lewis JS, Sharp TL, Laforest R et al (2001) Tumor uptake of copper-diacetyl-bis(N4- methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 42:655-661
155. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on the fibrosarcoma tumor model in vivo. Cancer Res 65:4202-4210
156. Lilja A, Lundqvist H, Olsson Y et al (1989) Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatmentinduced brain lesions. Acta Radiol 30:121-128
157. 11C]acetate in normal physiology. Eur J Nucl Med Mol Imaging 36:1453-1459
158. Lindstrom P, Sehlin J (1986) Aromatic amino acids and pancreatic islet function: a comparison of L-tryptophan and L-5-hydroxytryptophan. Mol Cell Endocrinol 48:121-126
159. 11C-acetate. Eur J Nucl Med Mol Imaging 33:420-427
160. Liu RS (2000) Clinical application of (C-11)acetate in oncology. Clin Positron Imaging 3:185
161. Lovenberg W, Weissbach H, Undenfriend S (1962) Aromatic L-amino acid decarboxylase. J Biol Chem 237:89-93
162. Luong A, Hannah VC, Brown MS et al (2000) Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins. J Biol Chem 275:26458-26466
163. Lyrdal D, Boijsen M, Suurküla M et al (2009) Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 30:519-524
164. Martiat P, Ferrant A, Labar D et al (1988) In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 29:1633-1637
165. 11C-choline positron emission tomography/ computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 176:954-960, discussion 960
166. 18Ffluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 31:797
167. Maurer RI, Blower PJ, Dilworth JR et al (2002) Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem 45:1420-1431
168. Mittendorfer B, Sidossis LS, Walser E et al (1998) Regional acetate kinetics and oxidation in human volunteers. Am J Physiol 274(6 Pt 1):E978-E983
169. 11C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 34:181-184
170. 18F-DOPA PET and PET/CT. J Nucl Med 48:1577-1579
171. 18F-acetate PET in prostate cancer: may a choice be recommended? Eur J Nucl Med Mol Imaging 34:1704-1705
172. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. World J Surg Oncol 5:68
173. Narayanan TK, Said S, Mukherjee J et al (2002) A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. Mol Imaging Biol 4:147-156
174. 11C]methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498-507
175. Ng P, Rajendran JG, Schwartz DL et al (2003) Can [F-18] fluoromisonidazole PET imaging predict treatment response in head and neck cancer? J Nucl Med 44:128
176. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43:46-55
177. 11C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 48:43-52
178. 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 32:197-202
179. Ogawa T, Shishido F, Kanno I et al (1993) Cerebral gliomas: evaluation with methionine-PET. Radiology 186:45-53
180. Oriuchi N, Tomiyoshi K, Inoue T et al (1996) Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med 37:457-462
181. 18F-fluoro-L-DOPA PET. Program of the 42nd annual meeting of the European Society for Paediatric Endocrinology (ESPE), Ljubljana, Slovenia, 2 (abstract 5.09)
182. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43:181-186
183. 18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29:623-629
184. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44:556-558
185. Padhani A (2006) PET imaging of tumour hypoxia. Cancer Imaging 6:S117-S121
186. 11C]choline. J Label Comput Radiopharm43:195-203
187. 18F] Fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678-687
188. 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 47:256-261
189. Pearse AG (1969) The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 17:303-313
190. 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur JNuclMed Mol Imaging 39:57-71
191. 18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 179:482-484
192. 18F]fluorodeoxyglucose positron emission tomography. J Urol 169:1337-1340
193. 11C- choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 47:938-44
194. 18Ffluoroazomycin arabinoside. J Nucl Med 46:106-113
195. Pio BS, Park CK, Pietras R, et al (2006) Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imagin Biol 8:36-42
196. 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45:1293-1298
197. Podo F (1999) Tumor phospholipid metabolism. NMR Biomed 12:413-414
198. 11C-acetate. J Nucl Med 48:420-428
199. 18F]-Fluoroacetate, an analogue of C-11 acetate for tumor imaging. J Nucl Med 44:296
200. 18F]Fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 32:1018-1025
201. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464-1470
202. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47:393-403
203. Powles T, Murray I, Brock C et al (2007) Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 51:1511-1521
204. 18F]fluoroethyl)-L-tyrosine. Nucl Med Biol 34:305-314
205. 18F- fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27:439-445
206. 18F]fluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505-511
207. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245-2252
208. 18F-FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30:695-704
209. 18F] fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 24:417-428
210. Rasey JS, Grunbaum Z, Magee S et al (1987) Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 111:292-304
211. 18F- fluorodeoxyglucose? Eur J Nucl Med Mol Imaging 33:S38-S43
212. Reubi JC (2004) Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1):51-56
213. Ricci PE, Karis JP, Heiserman JE et al (1998) Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR 19:407-413
214. Rigo P, De Landsheere C, Melon P et al (1990) Imaging of myocardial metabolism by positron emission tomography. Cardiovasc Drugs Ther 4(Suppl 4):847-851
215. Rohren EM, Turkington TG, Coleman RE (2004) Clinical applications of PET in oncology. Radiology 231:305-332
216. 99mTc-sestamibi negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. Eur J Nucl Med Mol Imaging 33:453-459
217. 18F]FT and [3H]L-methionine in focal ischemia. Nucl Med Biol 33:1029-1035
218. 18F-fluoroethyl)-Ltyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med 2007 48:2056-2062
219. Sasaki M, Kuwabara Y, Yoshida T et al (1998) A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur J Nucl Med 25:1261-1269
220. 11Cmethionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 22:210-214
221. Sawle GV (1993) The detection of pre-clinical Parkinson's disease: what is the role of positron emission tomography? Mov Disord 8:271-277
222. 11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 52:423-429
223. 11C- choline positron emission tomography/ computerized tomography for preoperative lymph-node staging in intermediate-risk and highrisk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54:392-401
224. Schiepers C, Nuytes J, Bormans G et al (1997) Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 38:1970-1976
225. 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42:1800-1804
226. 18F] Galacto-RGD positron emission tomography. Neuro Oncol 11:861-870
227. 18F]FLT and positron emission tomography. Nat Med 4:1334-1336
228. Shields AF (2006) Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8:141-150
229. Shreve P, Chiao PC, Humes HD et al (1995) Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36:1595-1601
230. 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging 35:942-949
231. Sörensen J, Andrén B, Blomquist G et al (2006) The central circulation in congestive heart failure non-invasively evaluated with dynamic positron emission tomography. Clin Physiol Funct Imaging 26:171-177
232. 18F- fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med 49:721-729
233. 18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging 34:651-657
234. 11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 31:317-324
235. Swinnen JV, Van Veldhoven PP, Timmermans L et al (2003) Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302:898-903
236. Takahashi N, Fujibayashi Y, Yonekura Y et al (2000) Evaluation of 62Cu labeled diacetyl-bis(N4- methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 14:323-328
237. 18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 33:1285-1289
238. 18F-FDG in patients with cirrohosis or chronic liver disease. J Nucl Med 51:1699-1706
239. 11C-methionine PET/TC. Contrast Media Mol Imaging 3:157-163
240. Tannock I, Guttman P (1981) Responses of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer 42:245-248
241. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694-699
242. 11C-choline PET/CT. Radiology 244:797-806
243. 18F]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol 6:172-179
244. Torii K, Tsuyuguchi N, Kawabe J et al (2005) Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med 19:677-683
245. Tsuyuguchi N, Sunada I, Iwai Y et al (2003) Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 98:1056-1064
246. Tsuyuguchi N, Takami T, Sunada I et al (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery- in malignant glioma. Ann Nucl Med 18:291-296
247. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37:400-419
248. 11Cmethionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32:39-51
249. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315-3323
250. Volker JF et al (1940) The absorption of fluorides by enamel, dentin, bone, and hydroxyapatite as shown by the radioactive isotope. J Biol Chem 134:543-548
251. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
252. 18F] Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 3:44
253. Weber W, Bartenstein P, Gross MW et al (1997) Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 38:802-808
254. 18F]Fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging. 32:422-429
255. 11C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 62:5698-5702
256. 18Ffluoroethyl)- L-tyrosine for tumor imaging. J Nucl Med 40:205-212
257. Whal L, Nahmias C (1997) Modeling of fluorine-18-6-fluoro-L-Dopa in humans. J Nucl Med 37:432-437
258. 18F) fluorotyrosine (see comments). J Nucl Med 32:1338-1346
259. Wong TZ, Van der Westhuizen GJ, Coleman RE (2002) Positron emission tomography imaging of brain tumours. Neuroimaging Clin N Am 12:615-626
260. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 32:742-748
261. 11C-choline PET: comparison with 18-F-FDG PET. J Nucl Med 49:1245-1248
262. 18F-FDG-PET. Mol Imaging Biol 10:281-287
263. 11C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging, Nov 14
264. Yoshimoto M, Waki A, Yonekura Y et al (2001) Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28:117-122
265. Zeisel SH (1981) Dietary choline: biochemistry, physiology and pharmacology. Annu Rev Nutr 1:95-121